Samsung Bioepis is reporting first year results from their phase 3 study of a proposed lucentis biosimilar (SB11). A biosimilar is a biological product (derived from a living organism) that shows no clinically meaningful differences from another biologic (eg. Lucentis). This study has shown that, at 52 weeks, primary end points were met for visual [Read More]
Category: Research and Developments
Vitamin D3 and Omega-3 Offer No Protection Against AMD
Observational studies have suggested that higher intake or blood levels of vitamin D and marine omega-3 fatty acids may be associated with lower risks of age-related macular degeneration (AMD). A recent large randomized trial (VITAL), however, has concluded that supplementation with vitamin D3 and marine omega-3 fatty acids actually had no significant overall effect on [Read More]
Smoking and Wet AMD Treatment
It has long been known that cigarette smoking reduces levels of plasma antioxidant, which protects retinal cells. It is also suspected as a contributor to cataract formation, restriction of night vision, and amblyopia (“lazy eye”). As reported in the September 2020 issue of the journal, Retina, a research team has confirmed the effect of smoking [Read More]
Levodopa may improve vision in patients with Wet AMD
Investigators have determined that treating patients with the early wet form of age-related macular degeneration (AMD) with levodopa, stabilized and improved their vision. Levodopa is a safe and readily available drug commonly used to treat Parkinson’s disease, The drug reduced the number of treatments necessary to maintain vision, and as such, will potentially reduce the [Read More]
Zimura® Shows Significant Suppression of Geographic Atrophy
IVERIC bio, Inc. has announced positive Phase 3 results from its GATHER1 clinical trial with Zimura® (avacincaptad pegol). As published in the September issue of Ophthalmology®, Zimura® met its pre-specified primary efficacy endpoint at 12 months and reached statistical significance in GATHER1, an international, multicenter, randomized, double masked, sham controlled clinical trial. Zimura® inhibits complement [Read More]